Sign In
Buy ALDX
$1.54
-0.0600 (-3.75%)
At Close: Jul 31, 2026
Aldeyra Therapeutics' (ALDX) CEO Todd Brady on COVID-19 Development Update Conference Call - Transcript
06:40pm, Wednesday, 20'th May 2020
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) COVID-19 Development Update Conference Call May 19, 2020 08:10 AM ET Company Participants Joshua Reed – Chief Financial
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
12:12pm, Wednesday, 20'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 19) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * A
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immun
Aldeyra Explodes 30% After-Hours Ahead Of Covid-19 Update Today
05:48am, Wednesday, 20'th May 2020
Shares in Aldeyra Therapeutics Inc (ALDX) exploded 30% in after-hours trading on Tuesday, following news that the company will host a conference call and webcast at 8AM ET today to provide a COVID-1
The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test
12:00am, Wednesday, 20'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs May 19)
ADC Therapeutics SA (NYSE:...
Aldeyra Therapeutics to Host Conference Call and Webcast to Provide COVID-19 Development Update
08:05pm, Tuesday, 19'th May 2020
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call and webcast at 8:00 a.m. ET Wednesday, May 20, 2020 to provide a COVID-19 development update.
How Aldeyra (ALDX) Stock Stands Out in a Strong Industry
12:53pm, Friday, 15'th May 2020
Aldeyra (ALDX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
